Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EG&G (Edgerton, Germeshausen, and Grier) was a prominent American technology conglomerate that became a foundational entity in the life sciences and diagnostics industry. Founded in 1947 by MIT professors, the company initially focused on nuclear and defense technologies before diversifying into analytical instrumentation and specialized sensors. In 1999, EG&G acquired the analytical instruments business of Perkin-Elmer and subsequently rebranded the entire corporation as PerkinElmer, Inc. to leverage that brand's recognition in the healthcare and laboratory markets. This strategic pivot shifted the company's focus toward drug discovery, genetic testing, and environmental monitoring. The legacy of EG&G's engineering excellence lives on through the detection and imaging technologies now housed within Revvity and the modern PerkinElmer. While the EG&G name is no longer used in the life sciences sector, its contributions to photonics and automated laboratory systems remain integral to modern biotech research.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EG&G.